Use Google Voice to Reach Your Participants!

Read below to learn how the Cincinnati Site (CRS 2401) uses Google Voice, a free service, to improve communication with their REPRIEVE participants!

The Cincinnati CRS created a Standard Operating Procedure that allows study staff to share one Gmail account ([IDCResearchInfo@gmail.com](mailto:IDCResearchInfo@gmail.com)) and gives them access to services like Google Voice.

Google Voice provides a Gmail account holder with one free phone number, [click here](https://mailchi.mp/0e756321d674/c46vbcmmx9-4934741?e=[UNIQID]) for more information.

How is Google Voice helpful for participant retention to the Cincinnati CRS?

1. All calls are forwarded to an "All Call Nurses Line" to the participant, it is a regular local phone number.
2. SMS text messaging is available! The text messages are managed via web browser with one shared username and password.
3. When participants cannot be reached because a lack of phone minutes, text messages may still reach them because text messages are a fraction of a phone minute.
To implement this, the Cincinnati team has added text messaging as an option for participant communications preferences, this preference is updated annually. If the participant assents to this type of contact, most (or sometimes all) communication flows through Google Voice (appointment reminders, check-ins, questions etc.).

*Please utilize this tool according to your local IRB/EC requirements.

Thanks to the **Cincinnati CRS team** for sharing this helpful information!

If you would like to learn more about setting up Google Voice at your site, please email Emma at ekileel@mgh.harvard.edu.
Attending CROI?
Join Us At the REPRIEVE Investigator's Meeting!!!

We invite you to join us on Monday, March 9th between 12:15 and 1:30 PM for the REPRIEVE Investigator’s Meeting at CROI 2020.

In addition to trial updates, attendees will hear a keynote presentation from Dr. Sandra Wagner Cardoso discussing CVD parameters among people living with HIV in Brazil as well as three presentations utilizing REPRIEVE baseline data being shared for the first time:

- **Patterns of Antiretroviral Therapy Use and Immunologic Profiles at Enrollment in REPRIEVE**, presented by REPRIEVE Co-Investigator Dr. Carl Fichtenbaum.
- **An Evaluation of Baseline Kidney Function in the REPRIEVE Trial**, presented by REPRIEVE Co-Investigator Dr. Turner Overton
- **Physical Function Impairment and Frailty in Middle-aged People Living with HIV in the REPRIEVE Trial (PREPARE)**, presented by PREPARE Co-Principal Investigator Dr. Kristine Erlandson.

Lunch will be served at the meeting, therefore, if you haven’t done so already, we request that you register to attend the event.

[Click here to register for this important meeting](#) We look forward to seeing you there!

If you are attending CROI, the PREPARE Substudy (A5361s) team is presenting a poster!

**When:** Wednesday, March 11th, 2:30–4:00PM
**Presentation:** 0707 – PREVALENCE OF PHYSICAL-FUNCTION IMPAIRMENT AND FRAILTY IN MIDDLE-AGED PWH
**Presented During:** FUNCTIONAL STATUS AND FRAILTY – P-M08

Help Us With the 2020 Participant Newsletter!
Participant newsletters are an excellent way to update participants about REPRIEVE and help keep them engaged in the trial.

The Clinical Coordinating Center is currently developing the 2020 Participant Newsletter, and we could really use your help!

1. **Do you have a REPRIEVE participant who might want to contribute** a few words about why they are participating in REPRIEVE? If yes, please reach out to Emma Kileel by emailing ekileel@mgh.harvard.edu
2. If you know how many newsletters your site needs and in what languages, click here to provide the details, knowing this will help us begin to organize the distribution!

Last year over 3,000 paper copies of the Participant Newsletter were distributed in 8 different languages!

---

**Have You Heard About the REPRIEVE Ambassador Initiative?**

*Florida Department of Health CRS team members, Bomi, Mable, and Dr. Charurut Somboonwith with Clinical Coordinating Center representative, Emma Kileel.*

Members of the REPRIEVE Clinical Coordinating Center have been visiting sites across North America since February, 2019 as part of the REPRIEVE Ambassador Initiative!

The CCC team believes that site visits have helped them learn more about the conduct of REPRIEVE at each individual site and how the CCC can support sites in
their trial efforts. In turn, sites have shared that they have found the visits very informative and have helped site teams generate new retention ideas to implement through the remainder of the trial.

Katie and Emma hope to complete site visits in North America in 2020 and will begin international site visits in 2021.

Recognize the Importance of REPRIEVE During Heart Health Month!

Below are some REPRIEVE specific messages you can share on your site's social media pages*

"Did you know that people living with #HIV are 50–100% more likely to have a heart attack or another form of cardiovascular disease? Learn more about this HIV–CVD connection by visiting www.reprievetrial.org #HeartHealth"

"People with HIV are up to twice as likely to develop heart disease, including heart attack and stroke, compared to people without HIV. Learn more about how @NIH and @reprievetrial hope to reverse this trend: https://www.niaid.nih.gov/news-events/happy-heart-month-what-people-living-hiv-should-know"

"Did you know there’s a link between HIV and Heart Disease? The @reprievetrial is looking to get ahead of the problem by testing the use of statins to prevent heart disease in people with HIV – and they are well on their way! REPRIEVE is the largest randomized clinical trial and ACTG study to date with over 7500 volunteers enrolled!"

*These have been approved by the IRB for the CCC, please submit to your local IRB/EC as per your local requirements.

Recent Article Mentions
Importance of REPRIEVE!

Consistent with findings from other studies, the findings in this article suggest that HIV is associated with a higher risk of atherosclerotic cardiovascular disease (ASCVD) events, including myocardial infarction, stroke, and lower extremity arterial disease. The authors highlight that the results of REPRIEVE will be essential to demonstrate if statins are effective to prevent ASCVD events in people with HIV who are at low-to-moderate traditional CVD risk.

*Click here to read the full article!*

---

**Don't Forget! The Next Team/Site Call is Tuesday, April 21st, 2020 1:00 – 2:00 PM ET**

Team/Site Call Schedule:
- Tuesday, July 21st 1:00 – 2:00 PM
- Tuesday, October 20th 1:00 – 2:00 PM

If you have ideas or topics you would like to see covered in these calls, please email Katie Fitch at kfitch@partners.org. We would love to hear from you!

If you missed the January site call, [click here](#) to download slides.

---

**REPRIEVE (A5332): Are you up to date?**

*For A5332 please use:*
- Protocol Version 5.0 dated 04/01/2019
- MOPS Version 5.0 dated 11/29/2019
- A5332 LPC for ACTG Sites Version 5.0 dated 04/11/2019
- A5332 LPC for Non–ACTG Sites Version 5.0 dated 04/11/2019

These documents are on the [A5332 PSWP](#)
Mechanistic Substudy of REPRIEVE (A5333s): Are you up to date?

For A5333s please use
Protocol Version 5.0 dated 04/01/2019
MOPS Version 4.0 dated 04/10/2018
A5333s LPC Version 4.0 dated 03/23/2018
These documents are on the A5333s PSWP

For future reference, all newsletters are available on the REPRIEVE Website.
We welcome ideas and suggestions for future newsletters. Please submit any comments or suggestions to the REPRIEVE News team at reprieve.news@fstrf.org

REPRIEVE Trial Clinical Coordinating Center
Massachusetts General Hospital
55 Fruit Street, 5LON 207
Boston, MA USA 02144

Our mailing address is:
reprieve.news@fstrf.org

Want to change how you receive these emails?
You can update your preferences or unsubscribe from this list.